(Q46856408)

25 December 2017

review article

1 reference

title

Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks (English)

1 reference

25 December 2017

chronic allograft nephropathy

1 reference

1 reference

1

1 reference

25 December 2017

author name string

Josep M Campistol

series ordinal

2

1 reference

25 December 2017

language of work or name

English

0 references

publication date

16 December 2005

1 reference

25 December 2017

Nephrology Dialysis Transplantation

published in

1 reference

25 December 2017

volume

21

1 reference

25 December 2017

page(s)

562-568

1 reference

25 December 2017

issue

3

1 reference

25 December 2017

Chronic allograft nephropathy: An update

cites work

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI336

Strategies to improve long-term outcomes after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI336

The natural history of chronic allograft nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI336

Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI336

Sirolimus: its discovery, biological properties, and mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI336

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI336

Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI336

Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI336

De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI336

Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI336

Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI336

Conversion to sirolimus in solid organ transplantation: a Single-Center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI336

Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI336

An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI336

Low-dose sirolimus in combination with mycophenolate mofetil improves kidney graft function late after renal transplantation and suggests pharmacokinetic interaction of both immunosuppressive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI336

Rapamycin rescue therapy in patients after kidney transplantation: first clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI336

Rapamycin in patients with chronic renal allograft dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI336

Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI336

Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI336

A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI336

Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: a 2-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI336

Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI336

Nephrotoxicity of rapamycin: an emerging problem in clinical medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI336

Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI336

Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI336

Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI336

Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI336

Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI336

Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI336

21 January 2018

Identifiers

DOI

10.1093/NDT/GFI336

1 reference

25 December 2017

PubMed ID

16361278

1 reference

25 December 2017